Form 4: Jaguar Health's Chief Scientific Officer Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Pravin R. Chaturvedi, Chief Scientific Officer of Jaguar Health, Inc., reports the acquisition of stock options and restricted stock units.
Summary
- On October 8, 2024, Pravin R. Chaturvedi, the Chief Scientific Officer of Jaguar Health, Inc., was granted stock options to purchase 39,376 shares of common stock at an exercise price of $1.29 per share.
- These options vest ratably on a monthly basis over 36 months from the grant date, contingent upon continued employment.
- Chaturvedi also received 4,922 restricted stock units, each representing a contingent right to receive one share of Jaguar Health's common stock.
- These restricted stock units vest in three equal annual installments beginning on October 8, 2025.
- Following these transactions, Chaturvedi directly owns 4,957 shares of Jaguar Health common stock and holds options for 39,376 shares.
- The grants were made pursuant to Jaguar Health's 2014 Stock Incentive Plan and approved by the board of directors on October 8, 2024.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a standard practice and indicates confidence in the executive and the company's future prospects. However, it also represents potential dilution for existing shareholders.
Positives
- The grant of stock options and restricted stock units to the Chief Scientific Officer aligns his interests with those of the shareholders.
- The vesting schedules for both the options and restricted stock units incentivize continued service and contribution to the company's success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and restricted stock units.
Industry Context
Stock option and restricted stock unit grants are common practices in the biotechnology industry to attract, retain, and incentivize key executives. These grants align executive compensation with company performance and shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also use stock options and restricted stock units to incentivize their executives.
- The vesting schedules (36 months for options, 3 annual installments for RSUs) are typical for such grants.
Stakeholder Impact
- Shareholders may experience slight dilution due to the potential issuance of new shares upon exercise of the stock options and vesting of restricted stock units.
- Employees are indirectly impacted as the grants incentivize the Chief Scientific Officer to contribute to the company's success.
Key Dates
| Date | Description |
|---|---|
| 2014 | Issuer's 2014 Stock Incentive Plan |
| 2024-05-23 | Issuer effected a 60-for-1 reverse stock split |
| 2024-10-08 | Date of earliest transaction, approval of option and restricted stock unit grants by the issuer's board of directors, and grant date of stock options and restricted stock units |
| 2025-10-08 | First vesting date for restricted stock units |
| 2034-10-08 | Expiration date of stock options |
| 2024-10-10 | Date of signature of the form |
Keywords
stock options, restricted stock units, Jaguar Health, insider trading, Form 4, executive compensation, Chief Scientific Officer, JAGX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.